{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:11:00Z","timestamp":1791889860376,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001298","name":"Presbyterian Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001298","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ygyno.2020.10.010","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T13:20:10Z","timestamp":1604150410000},"page":"302-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer"],"prefix":"10.1016","volume":"160","author":[{"given":"Suganthapriya","family":"Elayapillai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satishkumar","family":"Ramraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris Mangiaracina","family":"Benbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Bieniasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Pathuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitha Redempta","family":"Isingizwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan D.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Lightfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri A.","family":"Hunsucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille C.","family":"Gunderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.10.010_bb0005","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0010","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0020","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0025","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0030","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2009-09-243055","article-title":"The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma","volume":"115","author":"Spagnuolo","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0035","doi-asserted-by":"crossref","first-page":"11926","DOI":"10.1038\/s41598-018-30158-6","article-title":"Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways","volume":"8","author":"Dogra","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0040","first-page":"355","article-title":"Fenbendazole as a potential anticancer drug","volume":"33","author":"Duan","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0045","doi-asserted-by":"crossref","first-page":"71512","DOI":"10.18632\/oncotarget.17292","article-title":"Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer","volume":"8","author":"Ghasemi","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0050","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.18632\/oncotarget.3436","article-title":"Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells","volume":"6","author":"Hou","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0055","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13046-019-1303-z","article-title":"Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy","volume":"38","author":"Lin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0060","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/ijc.31585","article-title":"Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition","volume":"143","author":"Oh","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.10.010_bb0065","first-page":"11","article-title":"Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature","author":"Guerini","year":"2019","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0070","doi-asserted-by":"crossref","first-page":"30625","DOI":"10.1074\/jbc.M111.324228","article-title":"Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication","volume":"287","author":"Dogra","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.yexmp.2013.08.004","article-title":"TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type","volume":"95","author":"Rechsteiner","year":"2013","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0080","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/vco.12288","article-title":"In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells","volume":"15","author":"Lai","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0085","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/jo01342a016","article-title":"Systems with bridgehead nitrogen. \u03b2-Ketols of the 1-Azabicyclo [2.2. 2] octane series","volume":"31","author":"Nielsen","year":"1966","journal-title":"J. Organ. Chem."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0095","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1021\/bi049300+","article-title":"Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in \u03b1-or \u03b2-tubulin and increased microtubule stability","volume":"43","author":"Poruchynsky","year":"2004","journal-title":"Biochemistry."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0100","first-page":"3791","article-title":"Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole","volume":"29","author":"Chu","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0105","first-page":"937","article-title":"Enhancing the bioavailability of mebendazole by integrating the principles solid dispersion and nanocrystal techniques, for safe and effective management of human echinococcosis","volume":"44","author":"Chaudhary","year":"2016","journal-title":"Artific. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0110","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2014-01-548800","article-title":"PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH\/ROS balance","volume":"124","author":"Tessoulin","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0115","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/15384047.2015.1026482","article-title":"PRIMA-1Met induces apoptosis in Waldenstrom\u2019s Macroglobulinemia cells independent of p53","volume":"16","author":"Sobhani","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2020.10.010_bb0120","doi-asserted-by":"crossref","first-page":"83017","DOI":"10.18632\/oncotarget.12940","article-title":"PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK","volume":"7","author":"Lu","year":"2016","journal-title":"Oncotarget."},{"issue":"4","key":"10.1016\/j.ygyno.2020.10.010_bb0125","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ijc.32830","article-title":"Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53","volume":"147","author":"Ramraj","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.10.010_bb0130","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582034018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582034018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:57:12Z","timestamp":1758772632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582034018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S009082582034018X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.10.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}